Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results

 Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results

Pfizer Announces Tafamidis P-III Transthyretin Cardiomyopathy (ATTR-ACT) study results

Shots:           
  •  ATTR-ACT is a P-III global study with three-arms 20mg or 80mg PO QD vs PBO, including patients with variant (ATTRm), wild-type (ATTRwt), or hereditary
  •  ATTR-ACT results (N=441): Reduced all-cause mortality (29.5% vs. 42.9%); cardiovascular-related hospitalizations (0.48 vs 0.70) showing its efficacy, safety and tolerability enhancing QoL                
  •  In Mar’18, Japan granted SAKIGAKE designation whereas in May’18 the US FDA granted FT & BT designation to Tafamidis for ATTR-CM indication
Click here to read full press release/ article | Ref: Pfizer | Image:  Pfizer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post